Plitidepsin has a safe cardiac profile: a comprehensive analysis. - Wikidata - wikimedia - TriplyDB

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

http://www.wikidata.org/entity/Q35091717

about

Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II study Marine-derived angiogenesis inhibitors for cancer therapy.Plitidepsin: design, development, and potential place in therapy.Cardiomyocyte culture - an update on the in vitro cardiovascular model and future challenges.

P2860

Q35775249-B1EB9D40-FA73-4C79-A2EA-99E420FB0EE2 Q36994177-32B7321C-371D-48EF-A6A8-128E8A5C8D27 Q37603607-47D1E171-714A-4203-ACB8-B4A3D556F189 Q38167330-A99A9ED4-DDC0-43AD-87C7-A92F36CC9BD3

P2860

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

http://www.wikidata.org/entity/Q35091717

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

@ast

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

@en

type

label

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

@ast

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

@en

prefLabel

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

@ast

Plitidepsin has a safe cardiac profile: a comprehensive analysis.

@en

P1433

Q35091717-E47D982E-DC60-4A09-BC1F-AAD79824DF1A

P1476

Q35091717-1E2A4009-3C62-47D2-950C-238A17404C1B

P2093

Q35091717-0007898E-B71A-4CFE-A26E-0D2ECDC0465A

Q35091717-3E4E6089-1512-4382-ABB2-29DE21741C4F

Q35091717-4279802A-77FD-478E-B42A-99047B652634

Q35091717-4865D851-69A1-4899-B82D-74CB6B778135

Q35091717-4CF478A0-7B88-4823-83FE-78F6A394D47B

Q35091717-9C4B5E0E-8D47-417D-A86C-8028F177A4EA

Q35091717-BC868F88-24A0-4362-83AB-6867A0C1C7FF

Q35091717-D22992B1-B28C-41D3-A81B-CD77BD5E341E

Q35091717-FEA4A028-AA33-4063-A95D-8C489F7CBBCC

P2860

Q35091717-000FD110-A109-4D6E-B7D3-EC4FDB2EF725

Q35091717-065F6529-38C5-4B1D-A59B-9E72A3B0829E

Q35091717-072E7A5E-1D55-45C2-BDF7-56AA4CE06440

Q35091717-0B1A7F4F-F9B5-49C2-BF27-CC3CBBF54696

Q35091717-0E282B61-E93B-49C6-8ADE-0AC967470F6F

Q35091717-15A090E8-3CE1-4DF7-87AE-60DCE36A19F8

Q35091717-1B4FBC20-239B-401F-B55F-F3A31D581142

Q35091717-29C42021-E334-467F-B320-D3A15A7295FD

Q35091717-2DD167FD-DEBD-4396-9534-02A5B2F49B21

Q35091717-343C45F5-A96E-435C-B167-286091D9618E

P304

Q35091717-D4F7052E-9AAD-41B2-99B8-3D0E8B1D39EA

P31

Q35091717-8128B52F-473C-4CC2-B851-9EE19F11FB37

P356

Q35091717-E8BB2FC0-ABC4-4910-9FF8-B9EB95DB6B43

P433

Q35091717-A6D4961E-34C5-4666-8D97-3149F41FCD6F

P478

Q35091717-BFD29A68-B370-44CE-8007-9391DD3DE360

P50

Q35091717-FF2525D4-E567-4B75-91EB-0D526BD3269E

P577

Q35091717-7FFF42D1-100B-4E70-9170-A8BBC0C7EF26

P5875

Q35091717-4C3F9E9A-12C5-4321-A407-9EF9AAE2E3CE

P698

Q35091717-27DDC224-CF7B-42AE-A165-7D4C989C7146

P921

Q35091717-BE35DBB1-9901-4638-A301-7CC039628E71

P932

Q35091717-BEAE12C3-E180-46CC-8277-B18B774B47A6

P356

P1433

P1476

Plitidepsin has a safe cardiac profile: a comprehensive analysis

@en

P2093

Arturo Soto-Matos

http://www.w3.org/2001/XMLSchema#string

Bernardo Miguel-Lillo

http://www.w3.org/2001/XMLSchema#string

Carmen Kahatt

http://www.w3.org/2001/XMLSchema#string

Cinthya Coronado

http://www.w3.org/2001/XMLSchema#string

Claudia Silvia Corrado

http://www.w3.org/2001/XMLSchema#string

Elena Roy

http://www.w3.org/2001/XMLSchema#string

Pilar Lardelli

http://www.w3.org/2001/XMLSchema#string

Sergio Szyldergemajn

http://www.w3.org/2001/XMLSchema#string

Sonia Extremera

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac dysfunction in the trastuzumab clinical trials experience

In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells

Torsade de pointes associated with hypokalemia after anthracycline treatment in a patient with acute lymphocytic leukemia.

Phase II clinical and pharmacokinetic study of plitidepsin 3-hour infusion every two weeks alone or with dexamethasone in relapsed and refractory multiple myeloma.

The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects.

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome.

Predictors of cancer in patients with suspected pancreatic malignancy without a tissue diagnosis.

Anticancer agents and cardiotoxicity.

Molecularly targeted oncology therapeutics and prolongation of the QT interval.

P304

1007-1023

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/MD9061007

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51484353

http://www.w3.org/2001/XMLSchema#string

P698

21747745

http://www.w3.org/2001/XMLSchema#string

P921

P932

3131558

http://www.w3.org/2001/XMLSchema#string